BioNTech SE announced its acquisition of CureVac N.V. on June 12, 2025, involving a public exchange offer where 1 share of CureVac will be exchanged for Buyer ADS valued based on prior market conditions. The deal aims to consolidate CureVac's operations within BioNTech, leading to its deregistration as a public company.